Source: Therma Bright.
  • Therma Bright (THRM) has announced a C$6M private placement with institutional investors
  • The company will use the proceeds for general working capital purposes
  • It expects the placement to close on or about February 18, 2022
  • Therma Bright is a medical diagnostic and device technology company
  • Therma Bright (THRM) is down by 16.67 per cent trading at $0.3125 per share

Therma Bright (THRM) has announced a C$6M private placement with institutional investors.

The company will issue 20M units priced at $0.30 comprised of one common share and one common share purchase warrant.

Each warrant entitles the holder to purchase one common share for $0.375 for five years following the issuance date.

The company will use the proceeds for general working capital purposes.

It expects the placement to close on or about February 18, 2022.

H.C. Wainwright & Co. is acting as the exclusive placement agent.

Therma Bright is a medical diagnostic and device technology company. It developed the AcuVid COVID-19 Rapid Antigen Saliva Test.

Therma Bright (THRM) is down by 16.67 per cent trading at $0.3125 per share as of 12:43 pm EST.

More From The Market Online

Small-cap Canadian healthcare firm expands AI-screening at home and abroad

Diagnos (TSXV:ADK) uses AI through its CARA platform to help detect eye diseases like diabetic retinopathy & age-related macular degeneration

This healthtech company improves neurological care with AI

CeriBell is a healthtech company applying AI to neurological critical care, vastly improving diagnoses versus legacy technology.
Microsoft Vancouver office building

Microsoft offers voluntary buyouts to tens of thousands of employees

Microsoft (NASDAQ:MSFT) is offering voluntary buyouts to employees across several major divisions in the U.S., U.K., Canada, and India.